What question did this study set out to answer?

This research aims to evaluate the effectiveness of an ALK-mRNA vaccine in generating immune responses against ALK+ cancers.

ALK-mRNA Vaccine as Immunotherapy for ALK+ Cancers

View Full Paper

Ask AI

Bookmark

Authors

Researchers demonstrate a new ALK-mRNA vaccine induces strong immune response in ALK+ cancers, suggesting potential for treatment.

This research aims to evaluate the effectiveness of an ALK-mRNA vaccine in generating immune responses against ALK+ cancers.
Developed a codon-optimized ALK mRNA vaccine using lipid nanoparticles for effective delivery.
Administered varying doses of ALK-mRNA and peptide vaccines in mouse models.
Conducted in vitro assays to measure ALK protein expression and immunogenic responses.
Assessed in vivo T-cell responses and tumor growth after vaccination.
The ALK-mRNA vaccine induced robust anti-ALK CD8+ T cell responses, significantly stronger than peptide vaccines.
Both doses of the ALK-mRNA vaccine slowed tumor growth in a mouse model and extended survival.
No adverse effects were observed, indicating safety of the vaccine formulation.

Saccu et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark